[Asia Economy Reporter Junho Hwang] MedPacto announced on the 23rd that it has voluntarily withdrawn the comparative trial of Vactosertib and Imatinib combination therapy versus Imatinib monotherapy in progressive desmoid tumors (aggressive fibromatosis) (MP-VAC-206). The company explained, "As we revised our strategy to focus our capabilities on clinical trials of cancer types that can be commercialized early, we have adjusted our portfolio regarding the Vactosertib clinical trial."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
